Skip to main content
. Author manuscript; available in PMC: 2014 Jul 10.
Published in final edited form as: Cell Transplant. 2012;21(7):1419–1430. doi: 10.3727/096368911X627480

Figure 1. ActRIIB/Fc promotes the differentiation of human myoblasts even in presence of recombinant myostatin.

Figure 1

Myoblasts treated or not with ActRIIB/Fc at 500 ng/ml, were differentiated in myotubes for 3 days in the presence or absence of recombinant myostatin (rMSTN) at 500 ng/ml in the differentiation medium (Dulbecco’s modified Eagle’s medium (DMEM) with 2% serum). (a) Myotubes were stained in red with anti-myosin heavy chain (MyHC) and nucleus were stained in bleu with 4′,6-diamidino-2-phenylindole. The fusion is significantly reduced by rMSTN but this effect is blocked by ActRIIB/Fc. Scale bar = 0.2 mm. (b) The same effects are observed when the fusion index was calculated. Means + SD from three independent experiments are illustrated. *p < 0.05.